Oral Pimecrolimus

April 1, 2003

Maui, Hawaii - A 12-week dose-finding study evaluating oral pimecrolimus for the treatment of chronic plaque-type psoriasis has yielded encouraging safety and efficacy results, Alice B. Gottlieb, M.D., Ph.D., said at the annual Hawaii Dermatology Seminar, sponsored by the Skin Disease Education Foundation.

Related Content:

Pediatric Dermatology | News